Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03751865
Other study ID # JCWowCBT
Secondary ID UW 18-231
Status Recruiting
Phase N/A
First received
Last updated
Start date November 15, 2018
Est. completion date August 30, 2023

Study information

Verified date April 2021
Source The University of Hong Kong
Contact Yi Nam Suen, PhD
Phone 3917 9579
Email suenyn@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.


Description:

Eligible subjects with informed consent provided will be randomly assigned to the cognitive behavioural therapy (CBT) group or psychoeducation group. Each group consists of 8 session spanning for 8 week.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date August 30, 2023
Est. primary completion date August 30, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - women of age 18-64 - at-risk mental state as defined by the Comprehensive Assessment of At-Risk Mental States (CAARMS) - with an informed consent - able to understand Cantonese and read/write Chinese Exclusion Criteria: - those mental conditions that requires other treatment priorities (e.g., suicidal risk, substance abuse, current or past episodes of psychotic disorder, personality disorders) - those medical conditions that severely limits participation, comprehension, or adherence to the treatment (e.g., epilepsy, dementia, terminal medical illness); - those who are receiving structured psychotherapy or counselling

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
CBT
A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
Psychoeducation
A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.

Locations

Country Name City State
Hong Kong University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functioning: Measured by Social and Occupational Functioning Assessment Scale (SOFAS) Measured by Social and Occupational Functioning Assessment Scale (SOFAS). The SOFAS is an observer rating scale. Ratings should be based on subject's behavior during the last 1 month. The score ranges from 0-100. A higher score represents a better outcome. Changes from baseline to immediate, 6- and 12-month post-intervention
Primary Functioning: Measured by Role Functioning Scale (RFS) Measured by Role Functioning Scale (RFS). The RFS is comprised of four single rating scaled for evaluating the functioning of individuals in specified areas of everyday life. The four role functions assessed are:(1)Working: productivity, (2) Independent living and self care, (3) Immediate social network relationships, and (4) Extended social network relationship. The values on each of the four scales range from 1 (minimal level of role functioning), to 7 (hypothetically optimal level of role functioning). Each of the seven points on the scales is accompanied by a behaviorally defined description. Changes from baseline to immediate, 6- and 12-month post-intervention
Primary Conversion of psychosis Proportion of subject that convert from at-risk state to psychosis 12-month post-intervention
Secondary Positive psychotic symptoms Measurement of positive symptoms using the Chinese version of the Psychotic Symptom Rating Scales (C-PSYRATS). It comprises of the auditory hallucinations (AHS) and delusions subscales (DS). The AHS has 11 questions and the DS consists of 6 questions, each question has the responses ranging from 0-4. The higher score represents more severe positive psychotic symptoms. Immediate, 6- and 12-month post-intervention
Secondary Beliefs about the auditory hallucination Measured by the Beliefs About Voices Questionnaire (BAVQ-R). The BAVQ-R has 35 questions, the 4 responses range from disagree, unsure, slightly agree to strongly agree. The higher score represents more convicted belief about the voices. Immediate, 6- and 12-month post-intervention
Secondary Depressive symptoms Measured by the Calgary Depression Scale for Schizophrenia (CDSS). The scale consists of 9 questions, each has the response ranging from 0 to 3. The higher score presents more severe depressive symptoms. Immediate, 6- and 12-month post-intervention
Secondary Social anxiety :Measured by Liebowitz Social Anxiety Scale (LSAS) Measured by Liebowitz Social Anxiety Scale (LSAS). The LSAS consists of 24 questions, the rater has to rate from 0-3 in Fear or Anxiety domain or Avoidance domain for each of the 24 questions. The higher score represents more severe social anxiety. Immediate, 6- and 12-month post-intervention
See also
  Status Clinical Trial Phase
Terminated NCT03149107 - "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients" Phase 3
Recruiting NCT05131035 - Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk N/A
Completed NCT01269710 - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study N/A
Enrolling by invitation NCT05567848 - Accelerated TMS in Psychosis Phase 1/Phase 2
Recruiting NCT05052853 - Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer Phase 2
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Completed NCT01597141 - Psychosis: Early Detection, Intervention and Prevention N/A
Completed NCT00169988 - Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms N/A
Completed NCT03447548 - Neurofeedback Training for High Risk Psychosis N/A
Completed NCT06190483 - Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk N/A
Completed NCT01619319 - Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis N/A
Recruiting NCT05167396 - REtinal and VIsual Cortical Response in Early PSYchosis N/A
Terminated NCT00169949 - Aripiprazole Treatment of the Prodrome N/A
Recruiting NCT04338152 - Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial N/A
Recruiting NCT05142735 - Effects of NAC on Symptoms of CHR Patients N/A
Enrolling by invitation NCT05532683 - Feasibility Trial of a Lifestyle Intervention for CHR-P N/A
Enrolling by invitation NCT03970005 - Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis